Norway: Medical and Donor Requirements and Prohibitions
Start with the legal category
The Biotechnology Act (bioteknologiloven) and applicable regulations are binding law. Circulars issued by the Norwegian Directorate of Health explain interpretation and implementation; they may restate duties created by legislation or regulations and also make recommendations, but a circular is not legislation in itself. A clinic may apply medically justified protocols within its authorization. When a circular describes a requirement, check the underlying Act or regulation to determine its legal status.
It addresses medical and donor conditions, not the full rules on parentage, citizenship or recognition of a child born abroad. Those questions require separate analysis.
The key limit for surrogacy
Section 2-15 says that a fertilized embryo may be transferred only into the uterus of the woman who is to be the child’s mother. Where the gestational carrier is not intended to be the mother, that transfer is excluded from Norway’s assisted-reproduction framework. The law does not create a separate donor-screening route that makes such a transfer permissible.
The donor and clinical requirements below therefore concern ordinary assisted reproduction that Norwegian law permits; they do not create a legal route to surrogacy. A genetic link between an intended parent and the embryo does not, by itself, change the statutory rule about who receives the embryo. Treatment abroad raises separate questions under foreign law and Norwegian recognition rules, which this article does not decide.
Which donor combinations are permitted?
Donor sperm and donor eggs may be used separately in permitted forms of assisted reproduction, including IVF or ICSI, subject to treatment rules. For a couple, simultaneous use of a donor egg and donor sperm is prohibited. Donation of an already fertilized embryo is also prohibited.
There is a narrow statutory exception for a female couple: an egg retrieved from one partner may be fertilized and transferred to the other under § 2-15 (partner-egg donation, often called ROPA). For a single woman, the egg used in assisted reproduction must be her own. Donor-egg treatment is therefore not available to a single woman under this scheme. A clinic’s service list cannot override these statutory limits.
Donor age, consent and suitability
The statutory age limits differ by donor type. A sperm donor must be over 18. An egg donor must be over 25 and not older than 35. Donors must have legal capacity in personal matters and give written consent to use the sperm or unfertilized eggs for fertilization and to registration of identity. Consent may be withdrawn until fertilization has taken place.
The Directorate of Health recommends that a sperm donor should be over 25 and should not be over 45; these are recommendations, not statutory age limits. Guidance also calls for assessment of motivation, maturity, physical and mental health, and family history for signs of known hereditary disease. Egg donors should have suitable ovarian reserve, hormone status and ultrasound findings, and must discuss the psychosocial aspects with a health professional. Donors must understand that a donor-conceived child may later seek contact. Norwegian-bank guidance also requires registration in Norway’s Population Register and a permanent connection to Norway; do not assume those bank conditions describe every foreign programme.
The Act’s binding wording is “over 25”, while the Directorate circular summarizes the range as 25–35. Under § 2-9, a donor who is exactly 25 does not meet the statutory threshold; the circular’s shorthand should not be used to override the Act. Confirm that the bank applies the statutory wording. Under Directorate guidance, a donor ordinarily may not donate through another institution; approved banks may agree an exception with the donor’s consent if applicable rules are met.
Medical and infectious-disease screening
A sperm bank assesses sperm concentration, motility and suitability after freezing and thawing. Family history must not suggest a known hereditary disease. The Human Cells and Tissues Regulations set minimum serological screening for HIV-1/2, hepatitis B (HBsAg and anti-HBc), hepatitis C and syphilis; HTLV-1/2 testing applies to specified high-risk backgrounds. For non-partner sperm donation, the Regulations also require a urethral sample for gonorrhoea and a urine sample tested by PCR for chlamydia; both results must be negative. Banks may perform additional tests when justified. Separately, the Directorate’s donor-bank guidance calls for chlamydia and gonorrhoea testing for all sperm donors, using a urethral or first-void urine sample. Distinguish this guidance instruction from the Regulation’s specific sample and PCR requirements for non-partner sperm donation.
For sperm donated to someone other than the donor’s partner, the Regulations require at least 180 days of quarantine after the final donation, followed by testing of a new donor sample. The Directorate’s donor-bank guidance also describes a six-month quarantine and repeat-testing process. Under the applicable conditions, quarantine and repeat testing may be waived if the sample taken at the final donation is also tested by PCR for HIV, hepatitis B and hepatitis C. The Regulations also recognize a validated inactivation step under § 19(4), where applicable. Ask the bank to identify the applicable rule and document the basis for any exception.
Egg donors undergo clinical assessment including ovarian-reserve tests, hormone analysis and ultrasound. Minimum serological screening covers HIV-1/2, hepatitis B (HBsAg and anti-HBc), hepatitis C and syphilis; HTLV testing depends on risk factors. The Directorate’s guidance also requires chlamydia and gonorrhoea testing before each planned fresh-egg retrieval, with those samples collected within the preceding 14 days. A separate serological donation sample is collected within the 30 days before retrieval, and hormone stimulation must not begin until negative serological and microbiological results are confirmed. If the pre-retrieval donation sample is tested by both serology and PCR for HIV, HBV and HCV, six-month repeat testing and quarantine can be avoided; without PCR, follow-up blood tests are normally required after six months unless a prescribed validated inactivation route applies. The bank may request additional tests when needed. The applicable testing, timing and release rules are set out in the Human Cells and Tissues Regulations and are explained in the Directorate’s implementation guidance.
Approved providers and donor-use limits
A provider offering assisted reproduction must be approved by the Norwegian Directorate of Health for the relevant method. An establishment handling donor eggs or sperm must be approved by both the Directorate and the Norwegian Medical Products Agency (Direktoratet for medisinske produkter, DMP); if it stores donor gametes over time, it must also notify the applicable treatment-biobank register. Check the official list for the precise method: authorization to perform IVF does not automatically establish authorization to provide donor eggs or sperm.
Under Directorate guidance, sperm from one donor must not result in children in more than six families in Norway. An egg donor may donate at up to three retrievals. Banks register donor identity and relevant records in national registers, and gametes must not be released until applicable testing and handling requirements are met.
Medical assessment of the treatment recipient
For ordinary assisted reproduction, the woman receiving treatment may not be older than 46 at insemination or embryo transfer under § 2-3a. A doctor decides whether to offer treatment after an individual medical and psychosocial assessment, considering the applicant’s ability to care for a child and the child’s best interests. The applicant must submit a child-care certificate (barneomsorgsattest) obtained from the police.
The doctor may seek relevant additional information, but access to protected information requires the person’s consent. Written consent is required before treatment and must be renewed for repeated attempts; only adults with the required legal capacity may consent. Health, fertility diagnosis and clinical safety affect the plan. Meeting the age limit does not guarantee acceptance. These are rules for ordinary assisted reproduction, not a test of whether an intended parent may use a surrogate.
Donor identity and the child’s right to know
Donor conception in the regulated Norwegian system is not anonymous. The donor’s identity is registered, and recipients are not entitled to identifying information about the donor. Parents must tell the child that donor sperm or eggs were used as soon as advisable. The treating doctor must explain the age at which the child can request the donor’s identity.
The age depends on the type and date of donation. A person conceived using sperm donated before 1 January 2021 can request identity from age 18. For sperm donated on or after 1 January 2021, the right starts at 15. For eggs donated from 1 January 2021, the child can also request identity from age 15. The right belongs to the child. Knowing identity does not automatically make the donor a legal parent or create mutual rights and duties. If a foreign bank is used, ask how records will be registered and the child’s future access protected; do not assume a foreign anonymity promise overrides Norwegian requirements. For donor sperm used at Norwegian clinics from 2005 onward, identity information is available through the central donor register.
Checklist before starting or paying
Before signing or paying, get written answers: (1) which procedure and gametes will be used; (2) who will receive the embryo and how § 2-15 applies; (3) whether the clinic and donor bank are approved for that exact method; (4) donor age, test results and dates, quarantine/release status and registration; (5) the child’s identity-access age and the parent’s disclosure duty; (6) which conditions come from law, regulations or official guidance and which are clinic protocol; and (7) what each consent covers and when it can be withdrawn.
Ask for the official source or version of the clinic policy and keep copies of consent forms and medical documents. If a requirement is described as clinic policy, request its written clinical rationale and ask whether another authorized provider applies it differently. Do not rely only on advertising, a coordinator’s message or an informal promise.
If treatment is refused: next steps
If a clinic refuses ordinary assisted reproduction, request an individualized written explanation identifying the legal condition, medical finding or suitability concern behind the decision. Official guidance says the refusal should explain its factual basis and inform applicants of the right to complain. The complaint is first sent to the provider; if it does not change its decision, it is forwarded to the County Governor (Statsforvalteren). The stated deadline is four weeks from when the applicant knew or should have known enough to complain.
This route concerns refusal of healthcare/ordinary assisted reproduction; it does not authorize a procedure excluded by the embryo-transfer rule. If the plan involves a gestational carrier, a foreign clinic, stored embryos or an intended parent who will not gestate, obtain separate Norwegian legal advice before signing, transferring embryos or paying. Donor screening and clinic approval are meaningful safeguards, but they cannot override the statutory limit on where an embryo may be transferred.
Official sources
Official source titles are retained in their original language.
- Lov om humanmedisinsk bruk av bioteknologi m.m. (bioteknologiloven) (S1)
- Assistert befruktning med donoregg og donorsæd (S2)
- Krav til norske eggbanker og sædbanker (S3)
- Vurdering av egnethet ved assistert befruktning (faglig oppdatert 14. oktober 2026) (S4)
- Godkjente metoder for assistert befruktning (S5)
- Godkjente virksomheter - assistert befruktning og fertilitetsbevarende behandling (S6)
- Barnets rett til informasjon om donors identitet (S7)
- Forskrift om krav til kvalitet og sikkerhet ved håndtering av humane celler og vev (forskrift om håndtering av humane celler og vev), §§ 17, 19, 22–23 (S8)
